title: Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
authors.affiliation: Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
authors.forename: Laia
authors.initials: L
authors.lastname: Valls
authors.affiliation: Department of Medicine, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
authors.forename: Christopher
authors.initials: C
authors.lastname: Hoimes
authors.affiliation: Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
authors.forename: Andrew
authors.initials: A
authors.lastname: Sher
authors.affiliation: Advanced Molecular Imaging, Philips Healthcare North America, Cleveland, OH.
authors.forename: Lingzhi
authors.initials: L
authors.lastname: Hu
authors.affiliation: Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
authors.forename: Zhenghong
authors.initials: Z
authors.lastname: Lee
authors.affiliation: Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH.
authors.forename: Raymond
authors.initials: R
authors.lastname: Muzic
authors.affiliation: Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH. Electronic address: Norbert.Avril@Case.edu.
authors.forename: Norbert
authors.initials: N
authors.lastname: Avril
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D003287:Contrast Media; D038524:Diffusion Magnetic Resonance Imaging; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000556:secondary; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D019275:Radiopharmaceuticals; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D019275:Radiopharmaceuticals; C545932:(18F)fluoroethyltyrosine; D014443:Tyrosine; D019786:Gadolinium DTPA; D000077210:Sunitinib